Traditional Chinese Medicine (TCM) pharmaceutical manufacturing and distribution
Strategic Profile
In June 2026, the company announced a strategic acquisition of Best Praise International Limited for US$10.75M, acquiring five patents covering age-related diseases, neurodegenerative conditions, cognitive disorders, cardiovascular applications, antibacterial compounds, and drug delivery technologies. In February 2026, the company implemented a dual-class share structure on NASDAQ Capital Market. The company is a micro-cap player facing compliance challenges and operational restructuring.
Cyborg Score Rationale
The company received a Nasdaq staff determination notice in February 2025 regarding delinquency in filing its annual Form 20-F for fiscal year 2024, which serves as an additional basis for delisting. Stock performance has deteriorated sharply, with shares losing 51.8% over the past 12 months. The recent patent acquisition suggests strategic repositioning but minimal scale or market traction.
Top Insights
(February 2025) Nasdaq delisting notice for delinquent Form 20-F filing—material compliance risk
(June 2026) $10.75M acquisition of five pharmaceutical patents targeting age-related and neurodegenerative conditions—strategic pivot toward IP-based growth